Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea
Objective It has been established that use of proton pump inhibitors (PPIs) is associated with an increased risk of acquiring Clostridium difficile-associated diarrhoea (CDAD). However, it is not known whether the use of PPIs or histamine-2 receptor antagonists (H2RAs) concurrently with CDAD-targete...
Saved in:
Main Authors: | Thomas Louie, Karl Weiss, Mark A Miller, Kathleen Mullane, Derrick W Crook, Sherwood L Gorbach |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2015-12-01
|
Series: | BMJ Open Gastroenterology |
Online Access: | https://bmjopengastro.bmj.com/content/2/1/e000028.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infection (C. difficile-associated diarrhoea) in Ireland
by: Anke van Engen, et al.
Published: (2015-05-01) -
Clinical and Economic Consequences of Vancomycin and Fidaxomicin for the Treatment of Clostridium difficile Infection in Canada
by: Monika Wagner, et al.
Published: (2014-01-01) -
Fidaxomicin: A Novel Agent for the Treatment of Clostridium difficile Infection
by: George G Zhanel, et al.
Published: (2015-01-01) -
Nature’s Therapy for Recurrent Clostridium Difficile Diarrhea
by: Thomas Louie, et al.
Published: (2008-01-01) -
Clostridium difficile Outbreaks
by: Paul Bayardelle
Published: (2007-01-01)